News Related to ZL1310

Related coverage linked through entity extraction aliases.

Zocilurtatug pelitecan shows responses in pretreated extrapulmonary neuroendocrine carcinomas

Apr 26, 2026

Zocilurtatug pelitecan showed an overall response rate of 38.2% and a disease control rate of 55.9% in 34 patients with pretreated extrapulmonary neuroendocrine carcinomas. Grade 3 or higher treatment-emergent adverse effects occurred in 30.4% of patients.

Zai Lab Advances ZL-1310 in Phase 1b/2 Trial for Advanced Solid Tumors

Mar 19, 2026

Zai Lab announced an update on its Phase 1b/2 clinical study of ZL-1310, an experimental drug designed to treat advanced solid tumors with limited treatment options.